CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3505-3510

  Wang, Jing ^a   Xiao, Ling ^b   Luo, Chen Hui ^a   Zhou, Hui ^a   Zeng, Liang ^a   Zhong, Jingmin ^a   Tang, Yan ^a   Zhao, Xue Heng ^a   Zhao, Min ^a   Zhang, Yi ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CAOV3; CD44v6; Ovarian cancer; TGF ; catenin

Indexed keywords

BETA CATENIN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA; CD44V6 ANTIGEN; HERMES ANTIGEN; MESSENGER RNA; WNT PROTEIN;

ADULT; AGGRESSION; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; OVARY CANCER; PROTEIN EXPRESSION; CANCER STAGING; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY;

ANTIGENS, CD44; BETA CATENIN; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS;

EID: 84922328143     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3145     Document Type: Article

References (33)

1. Naora H and Montell DJ: Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355-366, 2005.
2. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006.
3. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
4. Lesley J, Hyman R and Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol 54: 271-335, 1993.
5. Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313, 1990.
6. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
7. Takaishi S, Okumura T, Tu S, et al: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27: 1006-1020, 2009.
8. Günthert U, Stauder R, Mayer B, Terpe HJ, Finke L and Friedrichs K: Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 24: 19-42, 1995.
9. Rall CJ and Rustgi AK: CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 55: 1831-1835, 1995.
10. Chen GY and Wang DR: The expression and clinical significance of CD44v in human gastric cancers. World J Gastroenterol 6: 125-127, 2000.
11. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P and Ponta H: CD44 is required for two consecutive steps in HGF/c-Met signaling. Gene Dev 16: 3074-3086, 2002.
12. Orian-Rousseau V, Morrison H, Matzke A, et al: Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 18: 76-83, 2007.
13. Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46: 1271-1277, 2010.
14. Cruz MC, Pereira AL, Lopes FF, et al: Immunohistochemical expression of E-cadherin and CD44v6 in squamous cell carcinomas of the lower lip and tongue. Braz Dent J 20: 64-69, 2009.
15. Cheng XX, Wang ZC, Chen XY, et al: Frequent loss of membranous E-cadherin in gastric cancers: A cross-talk with Wnt in determining the fate of beta-catenin. Clin Exp Metastasis 22: 85-93, 2005.
16. Todaro M, Gaggianesi M, Catalano V, et al: CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14: 342-356, 2014.
17. Yingling JM, Blanchard KL and Sawyer JS: Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022, 2004.
18. Siegel PM, Shu W, Cardiff RD, Muller WJ and Massagué J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100: 8430-8435, 2003.
19. Yao H, Ashihara E and Maekawa T: Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets 15: 873-887, 2011.
20. Daniels DL and Weis WI: Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 12: 364-371, 2005.
21. Yamamichi K, Uehara Y, Kitamura N, Nakane Y and Hioki K: Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 79: 256-262, 1998.
22. Misra S, Ghatak S, Patil N, et al: Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem 21: 2551-2559, 2013.
23. Yanamoto S, Yamada S, Takahashi H, et al: Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence. Int J Oncol 44: 1153-1162, 2014.
24. Wang H, Rana S, Giese N, Büchler MW and Zöller M: Tspan8, CD44v6 and alpha6 beta4 are biomarkers of migrating pancreatic cancer-initiating cells. Int J Cancer 133: 416-426, 2013.
25. Afify AM, Tate S, Durbin-Johnson B, Rocke DM and Konia T: Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors. Int J Biol Markers 26: 50-57, 2011.
26. Klatte T, Seligson DB, Rao JY, et al: Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. J Urol 183: 2403-2408, 2010.
27. Crispn JC, Keenan BT, Finnell MD, et al: Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum 62: 1431-1437, 2010.
28. Shi Jm, Zhou Z, Di Wen and Li N: Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 13:182, 2013.
29. Zöller M: CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11: 254-267, 2011.
30. Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25: 76-84, 2013.
31. Fuxe J and Karlsson MC: TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 22: 455-461, 2012.
32. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R and Kinch MS: E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10: 629-638, 1999.
33. Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487, 2004